{"transactions":[{"id":752505,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41896,"kind":"person","name":"Aromando Andrew","position":1,"cik":"0001976455","reported_name":"Aromando Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2026-06-03T20:30:34.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":260000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001493152-26-027088","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027088/ownership.xml","form_type":"4"}},{"id":905631,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41896,"kind":"person","name":"Aromando Andrew","position":1,"cik":"0001976455","reported_name":"Aromando Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Shares","published_at":"2026-02-13T12:00:22.000Z","date":"2026-02-11","kind":"purchase","planned":false,"acquired":true,"shares":29600,"price":0.8587,"value":25417.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.85 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":55100,"source":{"system":"sec-edgar","filing":"0001493152-26-006541","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006541/ownership.xml","form_type":"4"}},{"id":1589472,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":41896,"kind":"person","name":"Aromando Andrew","position":1,"cik":"0001976455","reported_name":"Aromando Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-07T17:43:26.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55570,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Company Common Stock subject to the Company Options vest as follows: (i) 1/6 of the Company Common Stock vested on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date."}],"balance_after":0,"derivative":{"exercise_price":16.66,"expiration_date":"2033-07-05","underlying":"Common Stock","underlying_shares":55570},"source":{"system":"sec-edgar","filing":"0000950170-24-028186","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028186/ownership.xml","form_type":"4"}},{"id":1589471,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":41896,"kind":"person","name":"Aromando Andrew","position":1,"cik":"0001976455","reported_name":"Aromando Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-07T17:43:26.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":371428,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price (\"Per Share Exercise Price\") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a \"Company Option\") vest as follows: (i) twenty-five (25) percent of the Company Common Stock vests on April 28, 2024, and (ii) the remainder vests in thirty-six equal monthly installments following such date."}],"balance_after":0,"derivative":{"exercise_price":9.66,"expiration_date":"2033-04-27","underlying":"Common Stock","underlying_shares":371428},"source":{"system":"sec-edgar","filing":"0000950170-24-028186","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028186/ownership.xml","form_type":"4"}},{"id":1589470,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":41896,"kind":"person","name":"Aromando Andrew","position":1,"cik":"0001976455","reported_name":"Aromando Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-07T17:43:26.000Z","date":"2024-03-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson (\"J&J\"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of March 7, 2024 (such date and time of such Merger, the \"Effective Time\"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each of these restricted stock units (\"RSUs\") represents a contingent right to receive one share of common stock of the Issuer (\"Company Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs vest as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the grant date of December 11, 2023, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-24-028186","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017024028186/ownership.xml","form_type":"4"}},{"id":1716612,"issuer":{"id":93373,"kind":"organization","name":"Ambrx Biopharma, Inc.","symbol":"AMAM"},"owners":[{"id":41896,"kind":"person","name":"Aromando Andrew","position":1,"cik":"0001976455","reported_name":"Aromando Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-12-11T17:19:44.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") payable in common stock of the Issuer granted to the Reporting Person on December 11, 2023 (the \"Grant Date\"). These RSUs were granted in connection with the completion of the year-end review process and will be issued pursuant to the Company's Amended and Restated 2021 Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest over thirty-six (36) months as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the Grant Date, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter."}],"balance_after":109263,"source":{"system":"sec-edgar","filing":"0000950170-23-069448","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1990550/000095017023069448/ownership.xml","form_type":"4"}},{"id":1833013,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":41896,"kind":"person","name":"Aromando Andrew","position":1,"cik":"0001976455","reported_name":"Aromando Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-07-07T16:05:50.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":389000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares (\"ADSs\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/6 of the Ordinary Shares subject to the option vest on January 5, 2024, and the remainder vests in ten (10) equal quarterly installments following such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer."}],"balance_after":389000,"derivative":{"exercise_price":2.38,"expiration_date":"2033-07-05","underlying":"Ordinary Shares","underlying_shares":389000},"source":{"system":"sec-edgar","filing":"0000950170-23-032229","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000095017023032229/ownership.xml","form_type":"4"}},{"id":1902988,"issuer":{"id":109604,"kind":"organization","name":"Ambrx Biopharma Inc.","symbol":"AMAM"},"owners":[{"id":41896,"kind":"person","name":"Aromando Andrew","position":1,"cik":"0001976455","reported_name":"Aromando Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-05T16:10:11.000Z","date":"2023-04-28","kind":"grant","planned":false,"acquired":true,"shares":2600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares (\"ADSs\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Grant awarded as an inducement grant in connection with the Reporting Person's appointment as Chief Operating Officer of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of the Ordinary Shares subject to the option vested on April 28, 2024, and the remainder vests in thirty-six equal monthly installments following such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer."}],"balance_after":2600000,"derivative":{"exercise_price":1.38,"expiration_date":"2033-04-28","underlying":"Ordinary Shares","underlying_shares":2600000},"source":{"system":"sec-edgar","filing":"0000899243-23-012347","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1836056/000089924323012347/doc4.xml","form_type":"4"}}]}